US biotech Novavax’ (Nasdaq: NVAX) shares were up nearly 6% at $111.90 late morning on Tuesday, after it announced an amendment to its existing agreement with the Serum Institute of India Private (SII) under which the latter will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate.
With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant.
“Today’s agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents,” said Stanley Erck, president and chief executive of Novavax, adding: “We continue to work with extraordinary urgency to develop our vaccine, now in Phase II clinical trials, and for which we anticipate starting Phase III efficacy trials around the world in the coming weeks.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze